3HAA-Iron Composition for Sepsis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Antibiotic resistance has rendered existing treatments ineffective against sepsis, particularly in elderly patients, necessitating the development of novel antibiotics that can combat antibiotic-resistant bacterial pathogens and reduce the hyperinflammatory response in septic individuals.

Innovation Solution

A composition containing 3-hydroxyanthanilic acid (3HAA) combined with either an iron chelator or an iron supplement, which sensitizes bacteria to changes in iron availability, thereby inhibiting bacterial growth and reducing the pathological hyperinflammatory response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing antibiotics are used to treat bacterial infections, then bacterial growth inhibition is achieved, but antibiotic resistance develops rendering treatments ineffective

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful factor of iron availability, which bacteria need for growth, into a beneficial therapeutic mechanism. By using iron chelators to deprive bacteria of iron or 3HAA to alter iron metabolism, the treatment exploits the bacteria's dependence on iron to kill them selectively, while the host's iron-regulating mechanisms protect it from harm. This approach bypasses traditional antibiotic resistance mechanisms.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the biochemical parameters of bacterial metabolism by interfering with iron availability and iron-dependent enzymatic pathways. 3HAA specifically alters the kynurenine pathway and iron metabolism, while iron chelators change the concentration of free iron available to bacteria. These parameter changes disrupt essential bacterial processes without relying on traditional antibiotic targets, thereby avoiding resistance development.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If iron chelators are used to inhibit bacterial growth, then bacterial proliferation is reduced, but the mechanism may not address the hyperinflammatory response in sepsis

Engineering Contradiction:

Improvebacterial growth inhibitionVSAvoidanti-inflammatory effect

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent makes the treatment multi-functional by combining 3HAA with iron chelators or supplements. This combination achieves two functions simultaneously: (1) iron deprivation or metabolic disruption to kill bacteria, and (2) modulation of the host's immune response to reduce pathological hyperinflammation in sepsis. The 3HAA component specifically addresses the inflammatory pathway while the iron-targeting component addresses bacterial growth, creating a versatile treatment that handles both aspects of the disease.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If high doses of antibiotics are administered to overcome resistance, then bacterial killing is enhanced, but adverse effects on host animals increase

Engineering Contradiction:

Improvebacterial killing efficiencyVSAvoidadverse effects on host

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent exploits the differential iron requirements and iron-regulating mechanisms between bacteria and host animals. Bacteria lack sophisticated iron-regulating systems and are highly vulnerable to iron deprivation, while host animals have protective mechanisms (ferritin, transferrin, hepcidin) that prevent iron deficiency. This allows selective toxicity against bacteria at doses that are safe for the host, avoiding the need for high-dose antibiotic therapy and its associated adverse effects.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of 3HAA with an iron chelator or supplement synergistically inhibits bacterial growth, effectively reducing the incidence of sepsis and its associated mortality, particularly in elderly patients, while minimizing adverse effects on host animals.

Implementation Method 1

3HAA sensitizes bacteria to changes in iron availability (both increasing iron media content through supplementation or chelation of iron)

Methodology Applied

Scientific EffectIron metabolism interference:

Implementation Method 2

Iron chelators act by binding available iron, making it easier for cells and tissues to move and excrete

Methodology Applied

Scientific EffectChelation:

Data Source

PatentUS20250127740A1Composition containing 3-hydroxyanthranilic acid and compounds that alter iron homeostasis and method of its use

Publication Date: 2025.04.24 THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

AI summary

A composition containing 3-hydroxyanthanilic acid (3HAA) and a compound that alters iron homeostasis (an iron chelator or an iron supplement). The combination may be used as a new antibiotic drug. Combining 3HAA with iron chelation may have the dual benefit of inhibiting pathogen growth while repressing the pathological hyperinflammatory response in septic individuals. The combination may be effective at preserving food by preventing bacterial growth.